Cannabidiol as a Potential Treatment for Anxiety Disorders, Neurotherapeutics. oct, vol.12, issue.4, pp.825-861, 2015. ,
Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders: CBD regulation of fear and drug reward processing, British Journal of Pharmacology, vol.174, pp.3242-56, 2017. ,
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish, Journal of the American Chemical Society. avr, vol.86, issue.8, pp.1646-1653, 1964. ,
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders, Philosophical Transactions of the Royal Society B: Biological Sciences. 5 déc, vol.367, pp.3364-78, 1607. ,
Regulatory Status of Cannabidiol in the United States: A Perspective. Cannabis and Cannabinoid Research, sept, vol.3, issue.1, pp.190-194, 2018. ,
Aspects légaux et analyse de produits à base de cannabidiol, Toxicologie Analytique et Clinique. mai, vol.31, issue.2, pp.48-57, 2019. ,
Labeling Accuracy of Cannabidiol Extracts Sold Online, JAMA, vol.318, issue.17, p.1708, 2017. ,
Le cannabidiol : état des lieux, Disponible sur, 2018. ,
Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment, Life Sci. 1 mai, vol.224, pp.120-127, 2019. ,
Cannabidiol in medical marijuana: Research vistas and potential opportunities, Pharmacological Research. juill, vol.121, pp.213-221, 2017. ,
Cannabidiol : où en est-on ? Le Courrier des Addictions, Disponible sur, 2017. ,
A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential. The Journal of Clinical Pharmacology, vol.7 ,
,
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients, Neuropsychopharmacology. mai, vol.36, issue.6, pp.1219-1245, 2011. ,
Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol, Schizophrenia Research. mai, vol.164, issue.1-3, pp.155-63, 2015. ,
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, Transl Psychiatry. mars, vol.2, issue.3, pp.94-94, 2012. ,
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial, AJP. mars, vol.175, issue.3, pp.225-256, 2018. ,
Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent, Current Drug Safety. 1 sept, vol.6, issue.4, pp.237-286, 2011. ,
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and Cannabinoid Research, janv, vol.2, issue.1, pp.139-54, 2017. ,
Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy, Pediatric Neurology. mars, p.0887899418311688, 2019. ,
, WHO | Controlled substances
,
, Usage médical du cannabis et des cannabinoïdes: questions et réponses à l'intention des décideurs politiques. Luxembourg: Observatoire européen des drogues et des toxicomanies, 2019.
Cannabis et cannabidiol : éléments de compréhension ,
Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination. Medicines (Basel). 23 févr, vol.6, issue.1, 2019. ,
, Luxembourg: Observatoire européen des drogues et des toxicomanies, Rapport européen sur les drogues 2019 : Tendances et évolutions, 2019.
FDA Regulation of Cannabis and Cannabis-Derived Products: Questions and Answers. FDA [Internet]. 4 mars, 2019. ,
, Disponible sur: /newsevents/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-questionsand-answers
, Avis issu de la première concertation organisée par le RESPADD sur la vaporisation du CBD -RESPADD
, Cannabidiol (CBD) le point sur la législation
,
, Arrêté du 22 août 1990 portant application de l'article R. 5132-86 du code de la santé publique pour le cannabis
, Vapoteuse au chanvre: la cour d'appel saisit la CJUE
,
Commission des stupéfiants et psychotropes. Agence Nationale de Sécurité du Médicament et des produits de santé, p.11, 2018. ,
, Commission de la transparence : SATIVEX, solution pour pulvérisation buccale
Cannabis à visée thérapeutique en France : le comité d'experts poursuit son programme de travail -Point d'Information -ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2014. ,
Galenic Preparations of Therapeutic Cannabis sativa Differ in Cannabinoids Concentration: A Quantitative Analysis of Variability and Possible Clinical Implications, Front Pharmacol, vol.9, p.1543, 2018. ,
Comité scientifique spécialisé temporaire « évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis thérapeutique en France ». Agence Nationale de Sécurité du Médicament et des produits de santé, 2018. ,
American Psychiatric Association. DSM-5 ®: manuel diagnostique et statistique des troubles mentaux, 2016. ,
The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): procedural validity of substance use disorders modules through clinical re-appraisal in a general population sample, Drug Alcohol Depend. 1 mars, vol.148, pp.40-46, 2015. ,
Recent Trends in the Prevalence of Marijuana Use and Associated Disorders in the United States, JAMA Psychiatry. mars, vol.73, issue.3, pp.300-301, 2016. ,
Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III, Am J Psychiatry, vol.01, issue.6, pp.588-99, 2016. ,
Les niveaux d'usage des drogues illicites en France en 2017. Observatoire français des drogues et des toxicomanies, 2018. ,
Combining cognitive behavioral therapy and contingency management to enhance their effects in treating cannabis dependence: less can be more, more or less, Addiction. sept, vol.107, issue.9, pp.1650-1659, 2012. ,
Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence, J Consult Clin Psychol. avr, vol.74, issue.2, pp.307-323, 2006. ,
,
, , vol.32, pp.46-55, 2010.
Treatment of Cannabis Use Disorder: Current Science and Future Outlook, Pharmacotherapy, vol.36, issue.5, pp.511-546, 2016. ,
The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder, Front Psychiatry, vol.10, p.63, 2019. ,
Pharmacotherapies for cannabis dependence, Cochrane Database Syst Rev, vol.28, p.8940, 2019. ,
Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation, JAMA, vol.284, issue.13, pp.1689-95, 2000. ,
Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse, Psychopharmacology (Berl). mars, vol.197, issue.1, pp.157-68, 2008. ,
Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial, Drug Alcohol Depend. 1 juill, vol.116, issue.1-3, pp.142-50, 2011. ,
The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users, Drug Alcohol Depend. 1 févr, vol.128, issue.1-2, pp.64-70, 2013. ,
, MARINOL 2,5 mg, capsule molle -ANSM : Agence nationale de sécurité du médicament et des produits de santé
Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse, Neuropsychopharmacology. juill, vol.38, issue.8, pp.1557-65, 2013. ,
Screening Medications for the Treatment of Cannabis Use Disorder, Int Rev Neurobiol, vol.126, pp.87-120, 2016. ,
Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users, Psychopharmacology (Berl), vol.233, issue.13, pp.2469-78, 2016. ,
Commission des stupéfiants et psychotropes ,
, Agence Nationale de Sécurité du Médicament et des produits de santé, 2013.
Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial, JAMA Psychiatry. mars, vol.71, issue.3, pp.281-91, 2014. ,
Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial, PLoS ONE, vol.13, issue.1, p.190768, 2018. ,
The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review, JCM. 19 juill, vol.8, issue.7, p.1058, 2019. ,
Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data, CNS Neurol Disord Drug Targets. mars, vol.9, issue.1, pp.55-64, 2010. ,
Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716), Neuropsychopharmacology. janv, vol.30, issue.1, pp.145-55, 2005. ,
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl), vol.194, pp.505-520, 2007. ,
Efficacy and safety of the weightloss drug rimonabant: a meta-analysis of randomised trials, Lancet, vol.17, issue.9600, pp.1706-1719, 2007. ,
Pharmacological interaction between cannabidiol and ?9-tetrahydrocannabinol, Psychopharmacologia, vol.33, issue.1, pp.53-70, 1973. ,
Pharmacological interaction of the effects of delta 9-transtetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats, Arch Int Pharmacodyn Ther. mai, vol.269, issue.1, pp.12-21, 1984. ,
Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content, Br J Pharmacol. avr, vol.72, issue.4, pp.649-56, 1981. ,
Cannabidiol: an overview of some pharmacological aspects, J Clin Pharmacol, vol.42, issue.S1, pp.11-19, 2002. ,
Pharmacological characterization of cannabinoids in the elevated plus maze, J Pharmacol Exp Ther. juin, vol.253, issue.3, pp.1002-1011, 1990. ,
Cannabidiol attenuates delta 9-tetrahydrocannabinol-like discriminative stimulus effects of cannabinol, Eur J Pharmacol. 17 juin, vol.125, issue.2, pp.301-305, 1986. ,
Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of ?9-tetrahydrocannabinol. Drug and Alcohol Dependence, avr, vol.94, issue.1-3, pp.191-199, 2008. ,
Cannabidiol potentiates ? 9 -tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats, Psychopharmacology (Berl), vol.218, issue.2, pp.443-57, 2011. ,
Cannabidiol interferes with the effects of ?9-tetrahydrocannabinol in man, European Journal of Pharmacology. sept, vol.28, issue.1, pp.172-179, 1974. ,
Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects, Psychopharmacology (Berl), vol.76, issue.3, pp.245-50, 1982. ,
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment, J Psychopharmacol (Oxford). janv, vol.27, issue.1, pp.19-27, 2013. ,
Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial, Cannabis Cannabinoid Res, vol.3, issue.1, pp.21-34, 2018. ,
Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study ,
, Br J Psychiatry, vol.197, issue.4, pp.285-90, 2010.
Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis, Neuropsychopharmacology. août, vol.35, issue.9, pp.1879-85, 2010. ,
Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis, Neuropsychopharmacology, vol.41, issue.8, pp.1974-82, 2016. ,
Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report, Integr Med (Encinitas). déc, vol.14, issue.6, pp.31-36, 2015. ,
Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report, J Clin Pharm Ther. avr, vol.38, issue.2, pp.162-166, 2013. ,
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology, Neuropsychopharmacology. févr, vol.35, issue.3, pp.764-74, 2010. ,
Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence, Subst Abuse, vol.9, pp.33-41, 2015. ,
, Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder -Full Text View -ClinicalTrials
, Cannabidiol: a Novel Intervention for Cannabis Use Problems? -Full Text View -ClinicalTrials.gov, p.83
,
, Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study -Full Text View -ClinicalTrials.gov
, Effects of Cannabidiol on Marijuana-seeking in Humans -Full Text View -ClinicalTrials.gov
,
, Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis -Full Text View -ClinicalTrials.gov
Interaction between cannabidiol (CBD) and ?(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids, Psychopharmacology (Berl). janv, vol.219, issue.1, pp.247-256, 2012. ,
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action, Braz J Psychiatry. sept, vol.30, issue.3, pp.271-80, 2008. ,
Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review, Pharmacol Biochem Behav, vol.90, issue.4, pp.501-512, 2008. ,
Cannabinoid receptor localization in brain, Proc Natl Acad Sci, vol.87, issue.5, pp.1932-1938, 1990. ,
Addictive potential of cannabinoids: the underlying neurobiology, Chem Phys Lipids. 31 déc, vol.121, issue.1-2, pp.267-90, 2002. ,
Traité d'addictologie, 2016. ,
Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra, Neuroreport. 10 févr, vol.8, issue.3, pp.649-52, 1997. ,
The endocannabinoid system in brain reward processes, Br J Pharmacol. mai, vol.154, issue.2, pp.369-83, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00398409
CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors, Neuropsychopharmacology. févr, vol.30, issue.2, pp.339-388, 2005. ,
URL : https://hal.archives-ouvertes.fr/inserm-00116578
Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats, Psychopharmacology (Berl). janv, vol.159, issue.2, pp.181-188, 2002. ,
Animal models of substance abuse and addiction: implications for science, animal welfare, and society, Comp Med. juin, vol.60, issue.3, pp.177-88, 2010. ,
Addiction and the brain: the neurobiology of compulsion and its persistence, Nat Rev Neurosci, vol.2, issue.10, pp.695-703, 2001. ,
It could be habit forming: drugs of abuse and striatal synaptic plasticity, Trends Neurosci. avr, vol.26, issue.4, pp.184-92, 2003. ,
Endogenous cannabinoids mediate longterm synaptic depression in the nucleus accumbens, Proc Natl Acad Sci, vol.99, issue.12, pp.8384-8392, 2002. ,
Effects of Cannabinoid Drugs on Aversive or Rewarding Drug-Associated Memory Extinction and Reconsolidation, Neuroscience, vol.01, pp.62-80, 2018. ,
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro, Br J Pharmacol. mars, vol.150, issue.5, pp.613-636, 2007. ,
Pharmacology of cannabinoid CB1 and CB2 receptors, Pharmacol Ther, vol.74, issue.2, pp.129-80, 1997. ,
Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor, Br J Pharmacol, vol.172, issue.20, pp.4790-805, 2015. ,
Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination, Braz J Med Biol Res. juill, vol.16, issue.2, pp.141-147, 1983. ,
Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug and Alcohol Dependence, vol.172, pp.9-13, 2017. ,
Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT 1A receptors in the dorsal raphe nucleus: Cannabidiol and brain reward, Addiction Biology. mars, vol.18, issue.2, pp.286-96, 2013. ,
A Cross-Sectional Study of Cannabidiol Users, Cannabis Cannabinoid Res, vol.3, issue.1, pp.152-61, 2018. ,
Self-medication with alcohol or drugs for mood and anxiety disorders: A narrative review of the epidemiological literature, Depress Anxiety, vol.35, issue.9, pp.851-60, 2018. ,
Self-medication of mood disorders with alcohol and drugs in the National Epidemiologic Survey on Alcohol and Related Conditions, J Affect Disord. juin, vol.115, issue.3, pp.367-75, 2009. ,
Self-medication of anxiety disorders with alcohol and drugs: Results from a nationally representative sample, J Anxiety Disord. janv, vol.23, issue.1, pp.38-45, 2009. ,
Relationship between cannabis and psychosis: Reasons for use and associated clinical variables, Psychiatry Res, vol.229, issue.1-2, pp.70-74, 2015. ,
Estimations 2011 des consommations de produits psychoactifs à 17 ans. Observatoire français des drogues et des toxicomanies, 2011. ,
, XLSTAT version 2019
Your data analysis solution ,
,
A randomized clinical trial of Motivational Interviewing to reduce alcohol and drug use among patients with depression, J Consult Clin Psychol. juill, vol.84, issue.7, pp.571-580, 2016. ,
Psychosocial interventions for cannabis use disorder, Cochrane Database Syst Rev. 5 mai, issue.5, p.5336, 2016. ,
The Role of the pharmacist in self-care and self-medication, 1998. ,
, Automédication : les bonnes pratiques
, Conseil National de l'Ordre des Médecins, 2019.
Notes from the Field: Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol -Utah, MMWR Morbidity and Mortality Weekly Report. 25 mai, vol.67, issue.20, pp.587-595, 2017. ,
The Trouble with CBD Oil, Med Cannabis Cannabinoids. 12 juin, vol.1, issue.1, pp.65-72, 2018. ,
, Annexe 2 -Réponse par email de la CNIL Bonjour Monsieur Marc MOINAS, Nous vous remercions de nous avoir contactés
, Dans le cadre de la réalisation de votre thèse en tant qu'interne en DES de psychiatrie, vous souhaitez savoir si vous avez des formalités à effectuer auprès de notre Commission
, Je vous indique que si les données que vous collectez sont anonymes, c'est-à-dire qu'elles ne vous permettent pas d'identifier directement ou indirectement une personne physique, dans ce cas il ne s'agit pas de données à caractère personnel
, Recherche médicale : comment procéder pour une thèse ou un mémoire